Bullish Storm Brewing for Injective Price After Canary ETF Filing
The Injective price is enjoying a wave of bullish momentum on the daily chart—and now, institutional interest is catching up.
Canary Capital, a U.S.-based hedge fund manager, has officially filed with the Securities and Exchange Commission (SEC) to launch the Canary Staked INJ ETF, a product designed to track the Injective price while also distributing staking rewards to investors.Â
The announcement comes at a time when INJ is already pressing up against key resistance levels, suggesting a confluence of technical and fundamental catalysts.
ETF Filing Boosts Sentiment Around Injective
The proposed ETF aims to simplify access to staking rewards—a core function of the Injective blockchain—by integrating them into a regulated exchange-traded product.
This would lower the barrier to entry for both retail and institutional investors who might otherwise be hesitant to self-custody or interact with on-chain staking platforms.
In its filing, Canary Capital cited “significant and growing demand” for regulated exposure to INJ, reinforcing the notion that investor appetite for next-gen decentralized finance (DeFi) protocols is maturing.
This filing adds Injective to Canary Capital’s ambitious list of pending crypto ETFs, which already includes products tied to Litecoin, Hedera, Sui, TRON, XRP, and the meme-inspired PENGU token. While none of these ETFs have yet been approved, the move underscores Injective’s rising profile in the eyes of institutional investors.
Bullish Technical Setup Points Toward Injective Price Breakout
On the technical side, recent Injective price action reinforces the bullish narrative. The daily chart shows a steady uptrend with rising closes and strengthening support from key exponential moving averages.
The 9-day EMA is pulling ahead of the 20-day EMA, a classic bullish signal indicating momentum is accelerating.
Daily chart for INJ/USD (Source: GeckoTerminal)
The MACD is widening in bullish territory, with the histogram suggesting growing buy-side pressure. RSI levels are also creeping into overbought territory, which may prompt some caution but also reflects sustained demand typical of a trending market.
Order Book Reveals Solid Support and Manageable Resistance
Order book data further strengthens the bullish case for the Injective price. Strong bid walls at $13.84 and $13.85 represent deep buy-side liquidity, indicating that traders are ready to accumulate even if prices pull back slightly.
These layers of support offer a buffer beneath the current level, suggesting a solid foundation for a continuation higher.
On the resistance side, modest ASK walls exist at $14.14 and $14.15. Clearing these would open the path to $15.00, representing an almost 8% potential upside from current levels. Given the proximity of these resistance points and the strength of underlying support, a breakout above $14.05 could see rapid follow-through.
Trading Opportunities: Long Setups Favored
With bullish momentum supported by both technical indicators and a strong fundamental backdrop, long trades present the more favorable risk-reward setup at this stage. A break and close above $14.05 could offer a compelling entry, with $15.00 as a first target and stops placed below the $13.12 support zone.
Short trades would only become viable if the Injective price fails to breach resistance and shows signs of weakening momentum—such as bearish divergences or large volume rejections. In that case, downside targets could include $13.12 or $12.98, though the strong bid walls below make a sharp reversal less likely.
Conclusion
The Injective price is riding a wave of momentum, with technical strength on the charts and a boost in fundamental interest from Canary Capital’s staking-based ETF proposal. If market sentiment holds and the resistance near $14.05 is breached, INJ could soon be testing higher levels. The ETF filing not only strengthens the investment case for Injective but also signals broader institutional validation of staking-based DeFi assets.
Disclaimer: The information presented in this article is for informational and educational purposes only. It does not constitute financial advice. Ecoinimist is not responsible for any losses incurred. Readers should exercise caution before acting on this content.
